AbbVie Inc. $ABBV Stock Holdings Boosted by IFM Investors Pty Ltd

IFM Investors Pty Ltd grew its position in shares of AbbVie Inc. (NYSE:ABBV) by 3.4% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 361,420 shares of the company’s stock after purchasing an additional 12,009 shares during the quarter. AbbVie accounts for 0.7% of IFM Investors Pty Ltd’s portfolio, making the stock its 21st largest position. IFM Investors Pty Ltd’s holdings in AbbVie were worth $78,605,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Bank of Jackson Hole Trust boosted its stake in AbbVie by 0.6% during the fourth quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock valued at $1,648,000 after buying an additional 44 shares in the last quarter. Eclectic Associates Inc. ADV raised its position in AbbVie by 0.8% in the fourth quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock worth $1,337,000 after acquiring an additional 45 shares in the last quarter. Imprint Wealth LLC lifted its holdings in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after acquiring an additional 45 shares during the last quarter. Hardin Capital Partners LLC lifted its holdings in AbbVie by 1.4% in the 4th quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company’s stock valued at $759,000 after acquiring an additional 46 shares during the last quarter. Finally, Dogwood Wealth Management LLC boosted its position in shares of AbbVie by 10.8% during the 4th quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock valued at $108,000 after purchasing an additional 46 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Trading Down 1.1%

Shares of ABBV opened at $251.45 on Wednesday. The business’s 50-day moving average price is $216.92 and its 200 day moving average price is $219.56. The stock has a market capitalization of $444.26 billion, a P/E ratio of 123.87, a P/E/G ratio of 0.78 and a beta of 0.32. AbbVie Inc. has a 1-year low of $184.38 and a 1-year high of $255.99.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same period in the prior year, the firm earned $2.46 earnings per share. The business’s quarterly revenue was up 12.4% on a year-over-year basis. On average, research analysts predict that AbbVie Inc. will post 14.28 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio is 340.89%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ABBV. Wells Fargo & Company set a $260.00 price objective on shares of AbbVie in a research note on Monday, June 22nd. Guggenheim reissued a “buy” rating and set a $249.00 target price on shares of AbbVie in a research note on Friday, May 1st. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Monday, June 8th. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Finally, Canaccord Genuity Group upped their price target on AbbVie from $265.00 to $273.00 and gave the company a “buy” rating in a report on Tuesday, June 23rd. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $253.81.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie and Genmab reported positive Phase 3 results for Epkinly/epcoritamab in relapsed or refractory diffuse large B-cell lymphoma, with the trial meeting its primary endpoint and suggesting a potential label expansion. Article Title
• Positive Sentiment: AbbVie received positive CHMP opinions in Europe for Rinvoq in severe alopecia areata and non-segmental vitiligo, which could broaden the drug’s addressable market and add future sales momentum if approved. Article Title
• Positive Sentiment: AbbVie’s newly announced $10.9 billion Apogee acquisition and other partnership milestones underscore management’s willingness to invest heavily in future growth and deepen its immunology and neurology pipeline. Article Title
• Neutral Sentiment: Analysts slightly trimmed FY2026 earnings estimates, but the revised forecast remains close to consensus, so this looks like a modest rather than a major headwind. Article Title
• Negative Sentiment: U.S. lawmakers opened an investigation into AbbVie’s clinical trials in China, citing possible national security, ethical, and data-protection concerns. Article Title

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.